Revenue ($USD) : $18,341,000,000
R&D spend : $1,026,000,000.00
Employees : 50,000
Fiscal year end : 12/31/22
CEO : Peter Arduini

During its first six months as a stand-alone company, GE HealthCare’s revenue grew nearly 8% year-over-year.

The Chicago-based medtech giant’s second quarter was strong enough that it upped its full-year guidance to 6-8% revenue growth. Imaging, patient care solutions and pharmaceutical diagnostics served as significant growth drivers in Q2.

GE HealthCare has been has been on a tear when it comes to forging partnerships to boost its business. In June, it announced that it would work with Johnson & Johnson’s DePuy Synthes in the spine space, pairing its OEC 3D Imaging System with the J&J unit’s extensive product portfolio. In March, GE HealthCare announced a long-term joint venture with Sinopharm as it seeks to make additional inroads in China’s medical device market. It’s also inked a 10-year medical device maintenance deal with Advantus Health Partners worth $760 million.

Other top news this year included the acquisition of Caption Health and its AI-powered image guidance tech. The FDA also cleared its Carescape Canvas patient monitoring platform. –CN